These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1682471)

  • 1. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers.
    Lamb KA; Washington C; Davis SS; Denyer SP
    J Pharm Pharmacol; 1991 Jul; 43(7):522-4. PubMed ID: 1682471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.
    Kirsh R; Goldstein R; Tarloff J; Parris D; Hook J; Hanna N; Bugelski P; Poste G
    J Infect Dis; 1988 Nov; 158(5):1065-70. PubMed ID: 3183418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
    Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
    J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs.
    Nieto J; Alvar J; Rodríguez C; San Andrés MI; San Andrés MD; González F
    Res Vet Sci; 2018 Apr; 117():125-132. PubMed ID: 29272720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and toxicity of amphotericin B/triglyceride emulsion formulations.
    Lance MR; Washington C; Davis SS
    J Antimicrob Chemother; 1995 Jul; 36(1):119-28. PubMed ID: 8537259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis.
    Levy MY; Polacheck I; Barenholz Y; Benita S
    J Med Vet Mycol; 1993; 31(3):207-18. PubMed ID: 8360812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
    Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
    J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity.
    Egito ES; Araújo IB; Damasceno BP; Price JC
    J Pharm Sci; 2002 Nov; 91(11):2354-66. PubMed ID: 12379920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion.
    Souza LC; Maranhão RC; Schreier S; Campa A
    J Antimicrob Chemother; 1993 Jul; 32(1):123-32. PubMed ID: 8226403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.
    Souza LC; Campa A
    J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes.
    Forster D; Washington C; Davis SS
    J Pharm Pharmacol; 1988 May; 40(5):325-8. PubMed ID: 2899626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the toxicity of a new lipid complex formulation of amphotericin B.
    Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
    J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures.
    Shadkhan Y; Segal E; Bor A; Gov Y; Rubin M; Lichtenberg D
    J Antimicrob Chemother; 1997 May; 39(5):655-8. PubMed ID: 9184368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal activity against Candida albicans of starch Pickering emulsion with thymol or amphotericin B in suspension and calcium alginate films.
    Cossu A; Wang MS; Chaudhari A; Nitin N
    Int J Pharm; 2015 Sep; 493(1-2):233-42. PubMed ID: 26231107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution.
    Randall SR; Adams LG; White MR; DeNicola DB
    Am J Vet Res; 1996 Jul; 57(7):1054-8. PubMed ID: 8807021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments.
    Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
    J Antimicrob Chemother; 2005 May; 55(5):727-34. PubMed ID: 15761070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the formation of amphotericin B-phospholipid complexes in Langmuir monolayers.
    Lance MR; Washington C; Davis SS
    Pharm Res; 1996 Jul; 13(7):1008-14. PubMed ID: 8842037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.
    Zia Q; Khan AA; Swaleha Z; Owais M
    Int J Nanomedicine; 2015; 10():1769-90. PubMed ID: 25784804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study.
    Souza LC; Saldiva PH; Campa A
    Exp Toxicol Pathol; 2000 May; 52(2):169-75. PubMed ID: 10965993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.